18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma-Reference-Cited by-同舟云学术

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma

Published:2021-07-06 Issue:6 Volume:23 Page:818-826
ISSN:1536-1632
Container-title:Molecular Imaging and Biology
language:en
Short-container-title:Mol Imaging Biol

Author:

Ruff Andrew,Ballard Hatcher J.,Pantel Austin R.,Namoglu Esin C.,Hughes Mitchell E.,Nasta Sunita D.,Chong Elise A.,Bagg Adam,Ruella Marco,Farwell Michael D.,Svoboda Jakub,Sellmyer Mark A.^ORCID

Funder

NIH Office of the Director

Burroughs Wellcome Fund

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11307-021-01627-8.pdf

Reference34 articles.

1. Subklewe M, Von Bergwelt-Baildon M, Humpe A (2019) Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother 46(1):15–24. https://doi.org/10.1159/000496870

2. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation 25(4):625–638. https://doi.org/10.1016/j.bbmt.2018.12.758

3. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377(26):2545–2554. https://doi.org/10.1056/nejmoa1708566

4. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):25312544. https://doi.org/10.1056/nejmoa1707447

5. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56. https://doi.org/10.1056/nejmoa1804980

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review;Frontiers in Oncology;2023-11-28

2. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy;Blood Advances;2023-11-02

3. FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects;Cancers;2023-02-07

4. Measurable residual disease after CAR T-cell therapy;Seminars in Hematology;2023-01

5. Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity;Seminars in Nuclear Medicine;2023-01